The mean marketing budget of more than 200 companies surveyed in the 2019 MM&M/Deloitte Consulting Healthcare Marketers Trend Report increased 26% to $10.5 million. That means nearly 92% of respondents reported a year-over-year budget increase, far more than the prior year. However, there are also warning signs that the fortunes of healthcare marketers could take a turn for the worse. (MM&M)

Purdue Pharma is considering filing for Chapter 11 bankruptcy protection as it faces 2,000 lawsuits accusing the company of contributing to the opioid crisis. Chapter 11 would allow the drugmaker to negotiate with plaintiffs in bankruptcy court. (Reuters)

The FDA has publicly shamed 15 retailers for allegedly selling tobacco products to minors. Walmart, Walgreens, and 7-Eleven were among the chains called out by the government agency. The FDA also requested information from more than three dozen e-cigarette companies that it said may have illegally introduced products. (CNBC)

Eli Lilly said it is planning to roll out a half-price version of its Humalog insulin. Lispro would cost $138 per vial, and it could serve as a treatment for diabetics until a “more sustainable” model is found, Lilly said. However, diabetics have pointed out that insulin costs considerably less than that figure in other countries. (CBS News)

Meanwhile, four senators are hoping to change FDA guidance to speed up the introduction of insulin biosimilars. Sens. Dick Durbin (D-IL), Tina Smith (D-MN), Bill Cassidy (R-LA), and Kevin Cramer (R-ND) said they are concerned that regulatory conditions could delay the introduction of biosimilar products to the market. (Endpoints)